Diego Martinez-Sanchez

Zaragoza, AR, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

Journal: Journal for immunotherapy of cancer
Published: November 25, 2025

Expansion and activation of NK cells supported by accessory cells. Phenotypic and functional characterization.

Expansion and activation of NK cells supported by accessory cells. Phenotypic and functional characterization.

Journal: Methods in cell biology
Published: July 19, 2025

A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.

A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.

Journal: Leukemia
Published: November 18, 2024

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia.

Journal: Journal of hematology & oncology
Published: November 05, 2024

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors.

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors.

Journal: Oncoimmunology
Published: July 22, 2024

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells.

CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells.

Journal: Blood
Published: October 19, 2023

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.

Journal: Journal for immunotherapy of cancer
Published: October 19, 2022

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia.

Journal: Journal for immunotherapy of cancer
Published: August 26, 2022

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.

A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 12, 2021

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing.

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing.

Journal: Clinical and translational medicine
Published: September 22, 2020

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.

Journal: Scientific reports
Published: July 24, 2020

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.

Journal: Journal for immunotherapy of cancer
Published: June 22, 2020
Showing 1-12 of 22

Last Updated: 09/26/2026